Summary
Unable to verify label alignment for the provided claims because the FDA label excerpts supplied do not contain information about product branding, pricing, pack size, regional cost differences, or general statements about clinicians’ prescribing patterns beyond specific labeled dosing/administration instructions.
Category Scores
Accurate Statements
Unsupported Statements
Abiraterone 250 mg can refer to different products (brand vs. generic).
The supplied prescribing information excerpts do not address brand vs. generic product naming or interchangeability.
Abiraterone 250 mg price varies by pack size (number of tablets).
The supplied prescribing information excerpts do not include pricing or pack-size cost information.
Abiraterone 250 mg price varies by country and pharmacy.
The supplied prescribing information excerpts do not include pricing information by country or pharmacy.
Abiraterone 250 mg price varies based on whether the medicine is sold as regular tablets or as part of a specific manufacturer’s pack.
The supplied prescribing information excerpts do not include pricing or manufacturer-pack information.
Clinicians typically prescribe abiraterone as a total daily dose (often 1,000 mg per day).
While the label excerpt specifies a recommended dose of 1,000 mg once daily for metastatic CRPC, the claim attributes this to 'clinicians typically' (a prescribing pattern) which is not stated in the provided label excerpts.
Clinicians typically instruct that the total daily abiraterone dose (often 1,000 mg per day) is taken as multiple 250 mg tablets.
The label excerpt supports 1,000 mg as four 250 mg tablets for metastatic CRPC, but the provided claim again frames this as 'clinicians typically instruct' rather than describing the labeled administration instructions.
The out-of-pocket cost for abiraterone depends on how many 250 mg tablets are needed per day and the tablet count per bottle/box.
The supplied prescribing information excerpts do not include out-of-pocket cost, reimbursement, bottle/box tablet counts, or cost determinants.
Abiraterone 250 mg prices differ by region.
The supplied prescribing information excerpts do not include regional pricing information.
Contradictions
Important Omissions
If discussing dosing, the label excerpt also specifies administration timing/constraints (empty stomach; no food 2 hours before and 1 hour after; tablets swallowed whole with water; do not crush/chew) and that prednisone is co-administered (e.g., 5 mg twice daily for metastatic CRPC).
Importance:
Moderate
The label excerpt includes important safety monitoring (e.g., monitor for hypertension/hypokalemia/fluid retention at least once a month; measure ALT/AST/bilirubin; monitor for adrenocortical insufficiency). None of these are addressed despite the claims touching on dosing context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims largely concern product labeling/price context and general prescribing patterns. However, inability to confirm label alignment for these non-label topics prevents assurance of accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about pricing/pack-size/region and 'clinicians typically' are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or reframe non-label pricing/pack-size/region statements. If discussing dosing, cite only labeled instructions (e.g., 1,000 mg = four 250 mg tablets once daily for metastatic CRPC with prednisone; empty-stomach timing; swallow whole; do not crush/chew) and include relevant labeled administration/safety requirements.